Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Zhimin Zeng; Xiaoying Qian; Fanrong Liu; Yong Wang; Yong Yuan; Chen Fang; Xinwei Zhang; Shangkun Yuan; Renfang Chen; Biao Yu; Tong Wang; Yan Yin; Yong Li; Anwen Liu

doi:10.3389/fimmu.2023.1269596

Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

Front Immunol. 2023 Sep 6:14:1269596. doi: 10.3389/fimmu.2023.1269596. eCollection 2023.

Authors

Zhimin Zeng^{1

2

3}, Xiaoying Qian^{4

5}, Fanrong Liu⁶, Yong Wang^{4

5}, Yong Yuan⁷, Chen Fang^{4

5}, Xinwei Zhang^{4

5}, Shangkun Yuan^{4

5}, Renfang Chen^{4

5}, Biao Yu^{4

5}, Tong Wang^{4

5}, Yan Yin⁸, Yong Li^{4

5}, Anwen Liu^{1

2

3}

Affiliations

¹ Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
² Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China.
³ Radiation Induced Heart Damage Institute of Nanchang University, Nanchang, Jiangxi, China.
⁴ Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
⁵ Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China.
⁶ Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
⁷ Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
⁸ Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.956982.].

Keywords: anlotinib; camrelizumab; immune checkpoint inhibitors; immunotherapy; pulmonary sarcomatoid carcinoma; tislelizumab.

Publication types

Published Erratum